Navigation Links
Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
Date:2/27/2013

TEL AVIV, Israel, February 27, 2013 /PRNewswire/ --

Bioassociate has initiated coverage on KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO).  The Initiation Report contains a detailed discussion of KaloBios' business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks.  The Initiation Report is available at: http://www.bioassociate.com/research-and-publications/publications/.

Dr. Ofir Levi , Bioassociate's CEO: "KaloBios is developing monoclonal antibody (mAb) therapeutics based on the company's proprietary Humaneered™ antibody technology platform, with focus on respiratory related indications. KaloBios' lead program, KB001-A has been licensed by Sanofi Pasteur in 2010 for the treatment of Pseudomonas aeruginosa-related hospital-acquired infections.  The total deal value of this licensing agreement is $290 million plus royalties, including a $35 million upfront payment.  KaloBios recently completed an initial public offering and is now trading on the Nasdaq Global Market.  

 We see great potential in KaloBios' technology platform and clinical development programs. Further clinical development advancements are likely to attract additional potential collaborators, which will increase investors' attention.  For these reasons we, at Bioassociate, decided to initiate analysis coverage with a target price of $10.1 per share, which reflects an upside of 47% over the current share price.

About Bioassociate

Bioassociate is an independent investment research firm specialized in the life-science sector.  Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage.  Bioassociate structures its teams with multidisciplinary members to conduct specific assignments.  The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.

Disclosure: 

The research report described in this press release is not constructed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer would be illegal.  Bioassociate is not soliciting any action based upon this material.  It does not take into account the particular investment objectives, financial situation, risk profile or other needs of individual investors.  Before acting on any advice or recommendation in this material, an investor should consider whether it is suitable for his/her particular circumstances and, if necessary, seek professional advice.  The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such.  Opinions expressed are Bioassociate's current opinions as of the date appearing on this material only; such opinions are subject to change without notice.  

Please read each report's full disclosures and analyst background on Bioassociate website, http://www.bioassociate.com, before investing.  Bioassociate is not a registered investment adviser or broker-dealer.

The research report described in this press release contains forward-looking data subject to risks and uncertainties that could cause actual results to differ materially from those projected.  These forward-looking data represent Bioassociate's judgment as of the date of this release.  Bioassociate disclaims, however, any intent or obligation to update this forward-looking data.

Contact:
info@bioassociae.com 
+972-3-541-5050


'/>"/>
SOURCE Bioassociate
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... today announced that data from its successful Phase 2a ... focal treatment for localized prostate cancer, will be presented ... 32 nd Annual European Association of Urology in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... offering. ... global oxygen therapy devices market to grow at a CAGR of ... Oxygen Therapy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... ... March 23, 2017 , ... Altec Products, Inc. , ... as their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution ... award recognizes The Resource Group for their outstanding relationship with Altec and their ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of ... Change and Your Health on VoiceAmerica, recently talked on her program about how she ... the occasion to remind listeners of an important distinction. World Water Day, Kleyne pointed ...
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):